The Myriad Litigation and Genetic Diagnostic Testing in Australia.

This article details a study conducted to ascertain whether the Myriad litigation has had a discernible effect on the availability and pricing of genetic diagnostic testing in Australia. It concludes that the impacts of the litigation have been minimal. The great area of uncertainty for Australian testing resides with method patents, where scope for restrictive case law remains. [ABSTRACT FROM AUTHOR]

Copyright of European Intellectual Property Review is the property of Sweet & Maxwell Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)